USING LIVE, RECOMBINANT BAKERS YEAST AS AN HIV VACCINE

使用重组活面包酵母作为 HIV 疫苗

• 批准号: 2646776
• 负责人: RICHARD C DUKE
• 金额: $ 9.99万
• 依托单位: GLOBEIMMUNE, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2000-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2646776
• 关键词: AIDS vaccines; HIV envelope protein; Saccharomyces cerevisiae; cellular immunity; cytotoxic T lymphocyte; human immunodeficiency virus 1; laboratory mouse; leukocyte activation /transformation; method development; vaccine development; vector vaccine

DESCRIPTION: (From the applicant's abstract) Cytotoxic T cell (CTL) immunity is considered to play a major role in reducing viral load early in HIV infection, and in slowing the rate of progression to AIDS. However, most of the current HIV vaccines in advanced human clinical trials, those consisting of HIV-derived proteins or killed virus, elicit strong antibody responses but are poor at inducing CTL-mediated immunity. We have developed a novel vaccine delivery system, termed HIVAX, consisting of non-pathogenic Baker s yeast, (Saccharomyces cerevisiae) which we have engineered to express the HIV-1 gp160 envelope protein. Preliminary studies in mice and pig-tailed macaques have revealed several important characteristics of our vaccine: 1) it stimulates both CTL- mediated and humoral immunity; 2) it does not require co-administration of adjuvants; 3) it contains no infectious material; 4) it appears to immunize when given orally;and 5) it can be engineered using recombinant DNA technology to express three or more protein antigens. In this proposal the investigator will: 1) determine whether vaccine elicits protective immunity in mice by showing that tumor cells expressing the HIV-1 envelope protein fail to form tumors in mice vaccinated with HIVAX; and 2) begin to evaluate in greater detail the immunogenicity and to optimize delivery of the vaccine. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述：（来自申请人摘要）细胞毒性T细胞（CTL） 免疫力被认为在早期降低病毒载量方面起主要作用 艾滋病毒感染，以及减缓艾滋病发展速度。 然而，目前大多数艾滋病毒疫苗在晚期人类临床 试验，那些由HIV衍生蛋白或杀死的病毒组成的试验， 强的抗体应答，但在诱导CTL介导的免疫方面较差。 我们已经开发了一种新的疫苗输送系统，称为HIVAX， 由非致病性面包酵母（酿酒酵母）组成 我们设计了它来表达HIV-1 gp 160包膜蛋白。 对老鼠和猪尾猕猴的初步研究显示， 我们的疫苗的重要特征：1）它刺激CTL- 介导和体液免疫; 2）它不需要共同施用 佐剂; 3）它不含感染性物质; 4）它似乎 当口服给药时免疫;和5）它可以使用重组 DNA技术表达三种或多种蛋白抗原。 在本提案中，研究者将：1）确定疫苗是否 通过显示肿瘤细胞表达 HIV-1包膜蛋白在接种了以下疫苗小鼠中不能形成肿瘤 HIVAX;和2）开始更详细地评估免疫原性， 来优化疫苗的输送。 拟议商业应用：不可用